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identified 295 spinal injury patients, with a mean age at index of 44 years, an
average follow-up time of 6 years, and of which 79% were males. For 67% of the
population we observed at least one UTI, which resulted in a care contact. Inter-
estingly, a quarter of the population used prophylactic antibiotics (J01XX05), cor-
responding to an average of 235 DDDs per year, amongst users. A majority of UTIs
were handled in primary care, while over 90% of costs were contributed by UTI-
related hospitalisations. The mean cost per UTI was 43,500 SEK, while estimates
varied considerably, with costs ranging from an average of 1,800 SEK for UTIs
handled in primary care to 177,200 SEK for inpatient care. CONCLUSIONS: In a
population of spinal injury patients, costs for catheter-associated urinary tract
infections are to a large extent driven by outlier, expensive hospitalisation. There
would be a large potential for cost savings if these hospitalisations could be
avoided.
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OBJECTIVES: To collect real-life data on costs and resource use, in order to under-
stand the economic burden of urinary tract infection (UTI) amongst a population
who has received self- catheterisation training. METHODS: We used the CEBRxA
database, which combines data from a public claims database for the South-West
region of Sweden, comprising around 1.5 million individuals, with national Swed-
ish registers on drug utilisation and mortality. We identified a population of pa-
tients who had received self-catheterisation training anytime between 2006 and
2009(procedure code GB005). UTIs were identified through the following ICD-10
codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P. A cost per UTI was calculated
through considering UTI-related care contacts that occurred within 14 days from
each other. RESULTS: We identified 989 patients, with a high mean age at index of
65 years, 79% males, and an average follow-up time of 1.5 years. The disease burden
of this population was mainly related to the genitourinary system, like retention of
urine, benign prostate hyperplasia, cystitis, and neurogenic bladder, although es-
sential hypertonia emerged as the third most common comorbidity. We observed
an average frequency of one UTI every two years, while around one-fifth of patients
had a yearly UTI-frequency of one or above. A majority of UTIs were handled in
primary care, while around 80% of costs were contributed by UTI-related hospitali-
sations. However, among female patients, inpatient care only contributed to 60% of
total costs. The mean cost per UTI was 10,500 SEK, while estimates varied, with
average costs ranging from 2,100 SEK in primary care, to 32,000 SEK for inpatient
care. CONCLUSIONS: Patients having received self-catheterisation training were
on average of higher age and male. UTI-related hospitalisation was a clear driver of
costs, although this effect was less pronounced for women.
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OBJECTIVES:Approximately 880,000 tonsillectomy/adenoidectomy procedures are
performed in the US annually. Hemostatic matrix (FLOSEAL) is used for adjunctive
hemostasis in a variety of surgeries, but the health economic rationale supporting
its application in tonsillectomy and adenoidectomy has yet to be established. A
systematic literature review was conducted in order to examine the evidence for
hemostatic matrix and to consider its value in reducing the burden of these
procedures. METHODS: Applying keywords and inclusion criteria, the PubMed,
EMBASE, and Centre for Reviews and Dissemination databases were queried for
studies published in English up to March 1, 2011. Reference lists and the American
Academy of Otolaryngology-Head and Neck Surgery database were also manually
searched. Data on costs, resource utilization, and health outcomes were extracted
and summarized. RESULTS: Four prospective, randomized controlled trials pro-
vided data on 187 patients treated with hemostatic matrix. In the two studies
utilizing crossover design, no patients in the hemostatic matrix groups required
electrocautery, whereas 3 of 35 (9%) and 4 of 34 (12%) patients, respectively, re-
quired adjunctive hemostatic matrix intraoperatively after failing electrocautery.
In all three studies measuring operating room time, use of hemostatic matrix re-
sulted in significantly shorter mean durations (range, 0.93 to 24.6 minutes) com-
pared to electrocautery (range, 9.53 to 32.6 minutes) (all studies, P0.05). Although
postoperative bleeding rates did not differ, hemostatic matrix-treated patients in
three of four studies reported significant reductions in postoperative pain scores
and narcotic consumption compared to electrocautery-treated patients (P0.05).
CONCLUSIONS: Published evidence suggests that hemostatic matrix is effective in
achieving intraoperative hemostasis during tonsillectomy/adenoidectomy. Given
the high volume of procedures, using hemostatic matrix during tonsillectomy and
adenoidectomy may be potentially cost saving due to resulting reductions in oper-
ating time and postoperative narcotic consumption. Further research may identify
patients who are more likely to benefit from hemostatic matrix in this indication.
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OBJECTIVES: Data visualization as a form of business intelligence and knowledge
discovery will democratize the use of large scale payer/claims and electronic med-
ical records databases. The goal of this analysis was to assess the feasibility of
utilizing Tableau Software™ to create a data visualization tool that would augment
data mining and analytic methods for understanding hospital costs and reim-
bursement patterns in cardiac catheterization and electrophysiology procedures.
METHODS: The Premier Perspective® database was utilized for this analysis. The
Premier Perspective® database houses data from over 600 hospitals and ambula-
tory surgery centers across the United States. Eligible procedures were those that
occurred during the year 2010 with the associated ICD-9 or CPT codes for either
cardiac catheterization or electrophysiology procedures. All data were imported
into Tableau Software™ and dashboards were created to visualize the data by
procedure costs and department costs. Summary statistics of hospital utilization,
total costs, components of costs, and hospital charges for both inpatient and out-
patient settings are available for exploration in a dynamic manner by each quarter
in 2010. Each dashboard is hosted in a secure online environment and fully inter-
active allowing for dozens of different filters to be applied. RESULTS: For the year
2010 there were 1,104,936 visits of cardiac related procedures With 164,210 unique
cardiac catheterization procedures and 22,263 cardiac electrophysiology proce-
dures. Custom developed dashboards show procedures (and associated volumes)
by in- and out- patient status, by ICD-9 or CPT code, department, costs and CMS
reimbursement levels. This data visualization tool makes it possible to quickly see
hospital cost breakdowns on dozens of different dimensions. CONCLUSIONS: Tab-
leau Software™ is a powerful tool to enable the health outcomes researcher to have
insights into complex multilevel data. Business intelligence tools developed in this
manner enable visual interaction and exploration of data for rapid hypothesis
generation and business intelligence.
Medical Device/Diagnostics – Patient-Reported Outcomes & Preference-Based
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OBJECTIVES: Patients suffering from ALS have a need for a multitude of medical
aids. Existing (bureaucratic) hurdles might create plenty of problems for people
with rare diseases. Uncertainty about provision of medical aids and substantial
waiting times limit patient’s ability to participate in the activities of daily living.
This study aims 1) to analyze problems in financing and provision of medical aids;
2) to explore differences in reimbursement decisions of private and social health
insurance (SHI); and 3) to explore patient satisfaction according to the type of
health insurance. METHODS: First, published and grey literature was used to anal-
yse payment flows and supply chain activities of the various actors involved in the
provision and payment of medical aids. Second, a survey of ALS patients (n20)
based on semi-standardized questionnaires was conducted . Gathered information
included patients’ demographic characteristics, information on coverage decisions
and problems in the provision of medical aids. Based on patient satisfaction, anal-
ysis of variance tests were performed to investigate differences in satisfaction
between SHI and privately insured persons. RESULTS: A majority of patients expe-
rienced problems in reimbursement decisions, particularly in the case of expensive
or individually customized technologies. These reimbursement problems were
more common among SHI insured persons. Both SHI insured and privately insured
persons complain about long duration processes of individual requests for meeting
the cost. Nonetheless, most patients stated that they were satisfied with the actual
provision of medical aids, including product and service quality. CONCLUSIONS:
Our results suggest that difficulties with medical aids’ reimbursement decision
processes are a common problem among SHI and private insured ALS patients.
Although the patient’s insurance type has an impact on these time-consuming
process. Consequently, there is a need for an interdisciplinary approach in the
provision of medical aids. Case managers might be a solution to overcome these
problems.
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OBJECTIVES: In advanced or complicated Parkinson’s disease (CPD), among other
treatment alternatives, patients can receive deep brain stimulation (DBS) or con-
tinuous duodenal levodopa-carbidopa infusion (CDLCI). This pilot study was de-
signed to understand the preferences of patients who face these treatment choices.
METHODS:Treatment attributes were identified based on a literature review, focus
groups with patients, caregivers, and interviews with clinicians. A discrete choice
experiment survey was developed, reviewed by clinicians and piloted with pa-
tients. Patients (potentially considering DBS or CDLCI) in Spain (n30) and the UK
(n10) completed the survey . Treatment attributes included surgery type, impact
on daily life, medication need, speech difficulties, movement control, dyskinesia,
and off-periods. Data were analyzed using a multi-level hierarchical logistic model.
RESULTS: Surgery type (DBS electric lead insertion in the brain vs CDLCI intraduo-
denal tube placement) was the most powerful predictor in the model, with a pref-
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